entertainment -WSS

entertainment

author：Wikipedia 2025-08-12 09:08:34 - browse：3647

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FDA panel gives mixed vote on blood pressure devices

WSS

Meta looks to target Twitter with a rival app called Threads

Drug firms test therapies to halt Alzheimer’s before symptoms arise

New case study details death in closely watched Alzhiemer's trial

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Neuroscience startup Neumora files for IPO

2024 GOP presidential candidates spar over abortion in debate

hotspot

entertainment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Doctor appointment wait times are getting worse

Activists slam private health insurers over coverage restrictions

Inside the fall of star MIT scientist David Sabatini

Activists slam private health insurers over coverage restrictions

Can food be medicine? And other questions about a new push

Hepatitis C has a cure — but many Americans still lack access to it

Apellis safety probe of eye disease drug centers on injection needle

The cancer drug shortage isn’t new — and neither are the solutions

FDA panel gives mixed vote on blood pressure devices

hotspot

AstraZeneca bets AAV gene therapy will still deliver the goods

7 people shot in DC, police say

PhRMA sues HHS over Medicare drug price negotiation

How to make Best Hospitals ratings actually useful for patients

CDC advisory panel says seniors 'may' get RSV vaccine

Winners, losers from Medicare’s list of drugs subject to price talks

entertainment

Wikipedia

leisure time

explore